Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — InfuSystem Holdings — Investor Presentation (November 2020)
23 slides from Infusystems's investor presentation, Nov 19, 2020
Slide 1: Enabling Continuity of Care for Patients, From the Clinic to Their Home
Enabling Continuity of Care for Patients, From the Clinic to Their Home Investor Presentation November 2020 | (NYSE American: INFU)
Slide 2: Forward-Looking Statement / Non-GAAP Measures
Forward-Looking Statement / Non-GAAP Measures Forward-Looking Statement ‘Certain statements contained inthis presentation are forward:tooking statements within the meaning of Section 27A of the Secuttes Act of 1933, a amended, and Seation 216 ofthe Secuttes Exchange Act of 1934, as amended, suchas s
Slide 3: Double-digit growth through two proven business platforms
Double-digit growth through two proven business platforms: Durable Medical Equipment (DME) and Integrated Therapy Services (ITS) *Madiat data as of 1/16/20 RT. TRUSTED. Providing best-in-class durable medical ‘equipment and patient services facilitating clinic-to-home care $10B North American Home D
Slide 4: Focus, Scale and Experience
Focus, Scale and Experience \ @ @®@ ©2000 Sore Leading North American provider of equipment and services with 100K+ device fleet 34-year history, perfected model in Oncology and now expandinginto multiple therapies Five major service areas in the U.S. and Canada with nearly 300 employees National sc
Slide 5: Two Proven Business Platforms
Two Proven Business Platforms Growth Driven by Market Share Gains and New Therapy Opportunities DME $29.6M (36%) DURABLE MEDICAL EQUIPMENT (DME) SUPPORT SERVICES ITS $51.5M (64%) Total 2019 Equipment and consumable Revenue: sales/lease to hospitals, clinics INTEGRATED THERAPY SERVICES (ITS) $81.1 Mi
Slide 6: Well-Diversified & Strategic Payer Relationships
Well-Diversified & Strategic Payer Relationships Percentage of Cash Collected by Payer 2019 Medicare and Private Pay: 2.4% ———_—______ Medicaid CMS: 1.1% ~ 6,500 Direct Pay Hospital and Alternate Site Customers Hospital/Alternate Site Direct Payr 48.5 7 Commercial Payer: 47.7% No Single Payer Greate
Slide 7: DME Platform
DME Platform Traditional Medical Distribution, Lower-Margin, High-Turn Model Source _ Devices Device Repair & — Maintenance © Pump rentals and VAR sales (new devices) © Broker/trader sales (used devices) @ Biomedical service and repair © Direct payer model: INFU is paid directly by the hospital/clin
Slide 8: ITS Platform
ITS Platform Unique and Scalable, High-Margin, High-Service Model Device Repair & Maintenance © Supply medical equipment and proprietary consumables for outpatient care @ Hospital, clinician and patient customer service © Third-party payer model: INFU is paid by the patient’s medical insurance provi
Slide 9: Competitive Advantages
Competitive Advantages Significant Barriers to Entry Based on Unique Focus, National Scale and Established Payer Network a Quality Control 180 9001 Certified and CHAP Certified. “The patient is at the center of everything we do.” exon cory. (infuSystem
Slide 10: Growth Strategy of ITS Platform
Growth Strategy of ITS Platform Adding New High-Margin Therapy Segments Go-to-Market Evaluation | Strategy | Launch Growth/Traction Established: Oncology } i I om ns geen | iscsi Wound Therapy (remy sat urrently ev (Over $900 million current realizable opportunities -—— Potential future therapy segm
Slide 11: Highly Scalable Existing Infrastructure
Highly Scalable Existing Infrastructure Foundation Builtin Oncology: Leverage lt Multiple New Therapies Can Be Added With Times (Pain, NPWT, Future Therapies) Minimal incremental Expense @) Oncology & Pain Management NPWT Offices and Logistics Future Therapies $a ear st experencn: + Full North Ameri
Slide 12: ITS Model: Platform Proven in Oncology
ITS Model: Platform Proven in Oncology InfuSystem ITS Value Proposition Opportunity: Oncology Home Treatment @ '* Large capital expense for clinics in addition to maintenance and nightly triage + Reduced staff available to help patients with infusion pump questions and billing Solution: Outpatient T
Slide 13: Third Quarter Financial Results
Third Quarter Financial Results Net Revenue Net Income AEBITDA” Op Cash Flow (2) See Appeadic A, 2020 2019 2020 2019 2020 2019 2020 2019 a 525m $21.51 Hy S2.2m Wi siim GE s7 su ME 5.21 GE ss.am HE 5.2 CinfuSystem
Slide 14: Third Quarter YTD Financial Results
Third Quarter YTD Financial Results Net Revenue Net Income AEBITDA” Op Cash Flow (2) See Appeadic A, 2020 2019 2020 2019 2020 2019 2020 2019 EE 572.7 EE HS 6.7m Iso.em SS s20.1m ME $12.2 ES $12.7 ME sosm
Slide 15: Full Year Financial Results
Full Year Financial Results 20) DET | ssi.im Net Revenue 2018 $67.1 2019 i $i4m I Net Income (loss) 2018 Wi (s1.1)m « 2019 MEE sis.2m AEBITD, 2018 ME $i3.sm 2019 MEE $13.9 Op Cash Flow 2018 MMMM siz.4m (1) See Appendin A CinfuSystem’
Slide 16: Financial Trend & Current 2020 Guidance
Financial Trend & Current 2020 Guidance po Net Revenues'!) & AEBITDA! os a.sita cnn * ; - _~ ss E i = ne wy = : ‘ [;. ous om on = = calicris NeRnian lhe pilots i 1. 20162017 consolidated everweshave been adjustedtoretecttheetfectotthe adoption ot ASC 606 a 2018, 2 SeeAppendaa. 3. We continveto prepa
Slide 17: Financial Trend & Current Targets
Financial Trend & Current Targets Cash Flows From Operations ss $180-$190 sis | $163 $130 sus $120 $105 90 | 7s 60 ss 30 $15 0 + (uemes) 20164 20178 20184 20194 20208 ME tama omtrom eros = Aan Natectrmatet tent SRE GATTO Canute Opie #E. SMART, TRUSTED. 2.0% ass 70% 153% | sso 23s + 10% SeU3AOY 12H J
Slide 18: Recent Accomplishments & Corporate Priorities
Recent Accomplishments & Corporate Priorities Dominant market share and sales increases in oncology home therapy market — Late 2018/2019 Proactive patient engagement initiative launched to improve revenue cycle management — Qi 2020 Entered negative pressure wound therapy market with partner, Cardina
Slide 19: Executive Team
19 Executive Team Seasoned Industry Experience, Including: Pharmaceutical, Health Care, Life Sciences, Medical Device, Automotive OEM, Public Accounting, Military, Retail, Consumer Brands, Digital Advertising, Consulting & High-Tech (infuSystem
Slide 20: Summary
Summary care from the clinic into the home, driving double-digit > ‘Two proven platforms that enable the delivery of patient revenue, cash flow growth and accelerating profit aging population, medical innovation, patientsatisfaction > Market opportunities driven by rising health care costs, an and o
Slide 21: Questions & Answers
(infuSystem SAFE. SMART. TRUSTED: Questions & Answers
Slide 22: Appendix A - GAAP to Non-GAAP Reconciliation
Appendix A- GAAP to NON-GAAP Reconciliation cota oobi ‘Twelve Months nde ‘ieee Month tnded December 31, a 3 Seotember 30, (itewsend) 2016 ey ey 2019 2019 Es) 209 2» ‘GAAP net ome (as) aay a0 amy 136 cc ome perc 23 Aausments: Ineresterpense pry ie 1an0 1908 1496 1p ed er tcome txprovnion (one) (a2) 1
Slide 23: Appendix B - Select Balance Sheet Data
Appendix B — Select Balance Sheet Data December31, December31, September 30, 2018 2019 2020 (in Thousands, Except Share Data) Cash and Cash Equivalents $ 4318 $ 2,647 $ 1,939 Available Liquidity () 13,471 21,258 17,515 ‘Working Capital, Less Cash 3,332 2,893 7,542 Medical Equipment, Net 23,488 33,22
InfuSystem Holdings — Investor Presentation (November 2020) on 6ix